CHEK1 and small cell lung carcinoma: CHK1 inhibitors have the potential to enhance DNA damage effects, and preliminary preclinical data suggest that CHK1 represents a promising target for small-cell lung cancer (SCLC), particularly in tumors exhibiting cMYC protein overexpression [123].